98%
921
2 minutes
20
Liquid biopsy offers unique opportunities for low invasive diagnosis, real-time patient monitoring and treatment selection. The phenotypic and molecular profile of circulating tumor cells (CTCs) can provide key information about the biology of tumor cells, contributing to personalized therapy. CTC isolation is still challenging, mainly due to their heterogeneity and rarity. To overcome this limitation, a microfluidic chip for label-free isolation of CTCs from peripheral blood was developed. This device, the CROSS chip, captures CTCs based on their size and deformability with an efficiency of 70%. Using 2 chips, 7.5 ml of whole blood are processed in 47 minutes with high purity, as compared to similar technologies and assessed by in situ immunofluorescence. The CROSS chip performance was compared to the CellSearch system in a set of metastatic colorectal cancer patients, resulting in higher capture of DAPI+/CK+/CD45- CTCs in all individuals tested. Importantly, CTC enumeration by CROSS chip enabled stratification of patients with different prognosis. Lastly, cells isolated in the CROSS chip were lysed and further subjected to molecular characterization by droplet digital PCR, which revealed a mutation in the APC gene for most patient samples analyzed, confirming their colorectal origin and the versatility of the technology for downstream applications.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541613 | PMC |
http://dx.doi.org/10.1038/s41598-019-44401-1 | DOI Listing |
J Med Chem
September 2025
Department of Pharmacy and Biotechnology, Alma Mater Studiorum─University of Bologna, Via Belmeloro 6, Bologna 40126, Italy.
Innovative, sustainable therapies are urgently needed for neglected vector-borne parasitic diseases. In this study, we leveraged cashew nutshell liquid (CNSL), an agro-industrial byproduct, to develop biobased phosphonium and ammonium salts (-) targeting parasite mitochondria. By combining CNSL-derived C8 alkyl chains with lipophilic cations, we synthesized novel compounds exhibiting highly potent and activity against and spp.
View Article and Find Full Text PDFACS Biomater Sci Eng
September 2025
Chemical Engineering, University of Waterloo, Waterloo, Ontario N2L 3G1, Canada.
Patient-derived tumor organoids (PDTOs) are promising 3D disease models for developing personalized treatment methods. However, conventional technologies for making PDTOs have limitations such as batch-to-batch variation and low throughput. Droplet microfluidics (DM), which utilizes uniform droplets generated in microchannels, has demonstrated potential for creating organoids due to its high-throughput and controllable parameters.
View Article and Find Full Text PDFSports Med
September 2025
Harvard Medical School, Boston, USA.
Background: Physical training influences competitive marathon performance, including training volume and training frequency changes (TFCs) pre-race. Training intensity distribution (i.e.
View Article and Find Full Text PDFLab Chip
September 2025
Department of Biomedical Engineering, Lund University, Lund, Sweden.
Droplet splitting plays an important role in droplet microfluidics by providing precise control over droplet size, which is essential for applications such as single-cell analysis, biochemical reactions, and the fabrication of micro- and nanosized material. Conventional methods of droplet splitting using obstructions or junctions in the microchannel have a clear limitation that the split ratio for a particular device remains fixed, while existing active splitting methods are constrained by low flow rates, the need for complex systems, or limitations to specific droplet types. In this study, we demonstrate that droplet splitting can be achieved simply using a one-dimensional standing-wave field excited within a microchannel.
View Article and Find Full Text PDFWe envision the Full-Body AI Agent as a comprehensive AI system designed to simulate, analyze, and optimize the dynamic processes of the human body across multiple biological levels. By integrating computational models, machine learning tools, and experimental platforms, this system aims to replicate and predict both physiological and pathological processes, ranging from molecules and cells to tissues, organs, and entire body systems. Central to the Full-Body AI Agent is its emphasis on integration and coordination across these biological levels, enabling analysis of how molecular changes influence cellular behaviors, tissue responses, organ function, and systemic outcomes.
View Article and Find Full Text PDF